Enovis(ENOV) - 2023 Q4 - Annual Results

Enovis Announces Fourth Quarter and Full Year 2023 Results • Continued strong momentum with fourth-quarter sales growth of 11%, organic growth of 8% • Reported a fourth-quarter net income from continuing operations of $0.05 per share with adjusted earnings per diluted share of $0.79 • Entering 2024 with strong operating momentum and an exciting slate of new product launches WILMINGTON, DE, February 22, 2024 (GLOBE NEWSWIRE)—Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth com ...